Nuvocid (oritavancin) - Melinta Therap, Menarini
Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy. (PubMed, Antimicrob Agents Chemother) - Oct 15, 2026 - "Every 2-week dosing strategies are expected to maintain therapeutic concentrations between doses. This strategy may be employed to reduce the cost of treatment and improve patient convenience." 
Journal • PK/PD data • Cardiovascular • Infectious Disease • Inflammation
http://www.ncbi.nlm.nih.gov/pubmed/42872918
 
Cecilia F Volk; Max Blumenthal; Nolan Thomas; Sin Yin Lim; Warren E Rose; Wesley D Kufel
 
Oct 15, 2026
 
Prev Next